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Introduction 48
Circadian rhythms are variations in physiology and behaviour that recur approximately every 24 49 hours. 1 They include rhythms of body temperature, hormone release, activity, concentration, mood, 50 eating and sleeping. Circadian rhythmicity is co-ordinated centrally by the suprachiasmatic nucleus in 51 the anterior hypothalamus 2 and plays a fundamental role in homeostasis and the maintenance of 52 both physical and mental wellbeing. 2,3 Disruption to circadian rhythmicity is associated with a range 53 of adverse health outcomes, including cardiovascular disease, obesity, diabetes and some cancers, 4-6 54 as well as increased risk for major depressive disorder (MDD) and bipolar disorder (BD). 7-9 55 56 Circadian rhythmicity is regulated by both exogenous environmental stimuli ("zeitgebers") and by 57 genetic factors. 10 Several core circadian clock genes are involved in autoregulatory 58 transcription/translational feedback loops that maintain cell-cycle function. 11 However, the control 59 of circadian rhythms is likely to be polygenic, with regulatory genes and pathways still to be 60 identified. 3,12 61 62 To date, the most commonly used measure of circadian phenotypes has been subjectively-reported 63 chronotype, defined as an individual's preference for morning or evening wakefulness and activity. 13 
64
Evening chronotype is more likely to be associated with adverse health outcomes. 3, [14] [15] [16] Recently, 65 genome wide association studies (GWAS) of chronotype, self-reported sleep duration, and 66 accelerometer-derived sleep traits have identified several independent genetic loci previously 67 implicated in the regulation of circadian function (including PER2, PER3, RSG16, AK5, FBXL13), in 68 addition to novel associated genetic loci. 17-22 69 However, as a subjective measure, chronotype can be vulnerable to response bias. It may also have 70 inconsistent associations with more objective measures of circadian rhythmicity. 23 In a recent study 71 of over 91 488 individuals in the UK Biobank cohort, we derived objective measures of rest-activity 72 rhythmicity from accelerometer data. 24 We found that low relative amplitude (RA), a measure of an 73 individual's rest-activity rhythm, was associated with several mood disorder phenotypes. 24 We now 74 extend this work by conducting a GWAS of low RA in the largest sample known to date from UK 75 Biobank. We also assess the degree of genetic correlation between low RA and several psychiatric 76 phenotypes, including attention deficit hyperactivity disorder (ADHD), BD, MDD, mood instability, 77 post-traumatic stress disorder (PTSD), schizophrenia, anxiety and insomnia. Further, within a group 78 of UK Biobank participants who were not part of the primary GWAS study (up to 141 000 individuals), 79 we test for association between increased polygenic risk score (PRS) for low RA and mood disorder 80 5 continuous 10-hour period (M10) and the least active continuous 5-hour period (L5) in an average 114 24-hour period, using the formula below: 28 115
M10 is the mean activity during the continuous 10 hour period containing maximum activity in each 116 24 hour recording period (midnight to midnight). L5 is the mean activity for the corresponding 5 117 hour period containing the minimum activity within the same recording period. For each individual, 118 the RA data point was the mean RA value across all included 24-hour periods (seven days). RA ranges 119 from 0 to 1, with higher values indicating greater distinction between activity levels during the most 120 and least active periods of the day. 121
Participants who provided accelerometer data for less than 72 hours or who did not provide data for 122 all one-hour periods within the 24-hour cycle were excluded from analyses. Participants were also 123 excluded if their data was identified by UK Biobank as having poor calibration. We also excluded 124 over 10 000 participants with data flagged by UK Biobank as unreliable (unexpectedly small or large 125 size) and participants whose wear-time overlapped with a daylight savings clock change. 24 In the 126 current sample (N=91,870), mean RA was 0·87 (SD=0·06; range 0·121-0·997), similar to previously 127 reported values in healthy populations, 8 however the distribution of RA values observed in our 128 sample was negatively skewed (Supplemental Figure 1) . 129
Genotyping and imputation 130
UK Biobank released genotypic data for over 500 000 participants using two genotyping arrays 131 specifically designed for UK Biobank with 95% shared marker content. 29 Approximately 10% of these 132 participants were genotyped using Applied Biosystems UK BiLEVE Axiom array by Affymetrix, with 133 the remaining participants being genotyped using Applied Biosystems UK Biobank Axiom Array. 134
Phasing on the autosomes was done using SHAPEIT3 using the 1000 Genomes Phase 3 dataset as a 135 reference panel. Imputation of single nucleotide polymorphism (SNP) genotypes was carried out 136 using IMPUTE4; the merged UK10K and 1000 Genomes Phase 3 reference panel, as used for the UK 137
Biobank interim genotype data release. Stringent quality control was applied to the data, described 138 in an open access document. 29 139
Primary GWAS of low relative amplitude 140
Our primary GWAS was a study of cases of low RA defined as cases with a mean RA greater than two 141 standard deviations below the overall mean RA, with the remaining participants as controls. 24 Before 142 proceeding with genetic analyses, exclusions were applied to the data. Individuals were removed 143 6 according to UK Biobank genomic analysis exclusions, failure of quality control, gender mismatch, 144 sex chromosome aneuploidy, ethnicity (not Caucasian), lack of accelerometry data, plus other 145 accelerometry exclusions, as noted above. For related individuals (first cousins or closer), a single 146 individual was randomly selected from each pair of related individuals for inclusion in the analysis. 147
After these (and the acclelerometry-based) exclusions, 71 500 individuals were available for GWAS. 148
Data was further refined by removing SNPs with an imputation score of <0·8, minor allele frequency 149 of <0·01 and Hardy-Weinberg equilibrium p<1x10 -6 resulting in 7 969 123 variants remaining. 150
The primary association analysis was conducted using logistic regression in PLINK; 30 an additive 151 allelic effects model was used with sex, age, genotyping array, and the first eight genetic principal 152 components as covariates. For the GWAS, genome-wide significance was less than p<5x10 -8 . 153
Secondary GWAS of RA as a continuous trait 154
The BOLT-LMM method allows the inclusion of related individuals within GWAS. This method relaxes 155 the assumptions of the standard GWAS, as used above, by using a mixture of two Gaussian priors 156 and is a generalisation of a standard mixed model. This mixed model accounts for both relatedness 157 and population stratification; this results in greater power when compared to principal component 158 analysis. 31 As above, individuals were removed according to UK Biobank genomic analysis exclusions, 159 failure of quality control, gender mismatch, sex chromosome aneuploidy, ethnicity (not Caucasian), 160 and lack of accelerometry data. After these exclusions, 77 440 individuals were available for this 161 GWAS. As above, genome-wide significance was less than p<5x10 -8 . Note that due to the imbalance 162 between cases and controls available for low RA, we were unable to use the BOLT-LMM approach 163 for the primary GWAS. 31 164
Expression quantitative trait locus (eQTL) analysis 165
The lead SNP from each locus, identified by GWAS, was assessed for the possibility of expression 166 quantitative trait loci (eQTLs). This genotype-specific gene expression was assessed using the GTEx 167 portal. The portal was also used to investigate tissue-specific expression for the implicated genes. 32 168
Gene-based analysis 169
The summary statistics from both the primary and secondary GWAS analyses were uploaded to 170 FUMA web application for gene-based analyses. 33 Gene-based analyses were carried out based on 171 the MAGMA method using all genetic associations within the summary statistics. 33,34 For these 172 analyses genome-wide significance was set at p<5x10 -5 . 173
Genetic correlations between low RA and psychiatric phenotypes 174
Linkage Disequilibrium Score Regression (LDSR) was applied to the GWAS summary statistics to 7 provide an estimate of SNP heritability (h 2 SNP). 35, 36 LDSR was also used to investigate genetic 176 correlations between low RA and anxiety, ADHD, BD, MDD, mood instability, PTSD, schizophrenia 177 and insomnia. The LD scores for these disorders were obtained using the summary statistics from 178 the Psychiatric Genomics Consortium, CNCR-Complex Trait Genomics group, and UK Biobank. ADHD, 179 BD, MDD, schizophrenia and insomnia were analysed using LD Hub. 36 To define neuroticism a score was taken from the 12-item neuroticism scale of the Eysenck 196 Personality Questionnaire-Revised Short Form (EPQ-R-S). 38,39 Individuals were given a score of 0 or 1 197 for a "no or yes" answer to each item, with total score from 0 to 12. 198 c) Mood instability 199 A "mood instability" outcome measure was also obtained from the EPQ-R-S questionnaire: for one 200 question participants were asked "Does your mood often go up and down?" and given the option to 201 answer "yes", "no", "don't know" or "prefer not to answer" 38 . Individuals who selected "don't know" 202 or "prefer not to answer" were coded as missing; this allowed the generation of a categorical mood 203 instability variable where those who answered "yes" were designated as cases and participants who 204 answered "no" were controls, those answering "don't know" and "prefer not to answer" were 205 excluded. 40 206 207
Association between PRS for low RA and affective disorder phenotypes 208 8
Associations between higher PRS for low RA and psychiatric diagnoses were examined in up to 76 209 018 individuals who had completed the MHQ and who were not included in the primary GWAS. 210 Similarly, associations between low RA PRS and mood instability/neuroticism were examined in 211 between 91 248 and 140 504 individuals (depending on the dependent variable) not included in the 212 GWAS. PRS including SNPs at 6 different significance thresholds (p<5x10 -8 , p<5x10 -5 , p<0·01, p<0·05, 213 p<0·1, p<0·5) were divided into quartiles, with the exception of p<5x10 -8 which was divided into 214 tertiles as only three different PRS were generated for this threshold. The top and bottom quantiles 215 were compared in logistic regression models that were adjusted for age, sex, Townsend deprivation 216 index, 41 genotype array and the first eight genetic principal components. False discovery rate (FDR) 217 correction was applied. 42,43 218 219 Results 220
GWAS of low RA 221
Our primary analysis was a case-control GWAS of low RA. The GWAS data showed only a slight 222 deviation in test statistics compared to the null (λ GC =1·016, Figure 1) ; this deviation may be due to 223 the polygenic architecture of low relative amplitude. SNP heritability (h 2 SNP ) accounted for less than 1% 224 of the population variance (h 2 SNP =0·0067, se=0·0054). The Manhattan plot for low RA GWAS is 225 presented in Figure 1 . Two independent genomic loci on chromosomes 1 and 22 were associated 226 with low RA at genome-wide significance, including three SNPs (described in Supplemental Table 1) 
GWAS of continuous RA 232
As a secondary analysis, we performed a GWAS of a continuous measure of RA using a BOLT-LMM 233 model. The BOLT-LMM GWAS showed a slight deviation in the test statistics compared to the null 234 (λ GC =1·054, Figure 2 ), again consistent with a polygenic architecture for RA. The h 2 SNP for RA as a 235 continuous measure accounted for greater than 8% of the population variance (h 2 SNP =0·085, 236 se=0·00035). Five SNPs, all localised to one locus on chromosome 2, were associated with 237 continuous RA at genome-wide significance (described in Supplemental Table 2 ). These SNPs 238 highlight the Meis Homeobox 1 (MEIS1) gene. Again, as noted above, these are intronic SNPs and 239 their exact effects are not known. 240 9
Expression quantitative trait loci (eQTL) analysis 241
The lead SNPs from both GWAS were assessed for potential eQTLs. Only the lead SNP found on 242 chromosome 22 (rs9611417) was associated with the expression of a nearby gene. Being 243 heterozygous at rs9611417 was associated with lower expression of RANGAP1 gene in oesophageal 244 mucosa in comparison to rs9611417 C allele homozygotes (Beta=-0·43, p=7·2x10 -5 , Supplemental 245 Figure 4) . 253
Genetic correlation between low RA and psychiatric phenotypes 254
There was preliminary evidence of genetic correlation between low RA and insomnia (r g =0·90, 255 se=0·42, p=0·033), suggesting that the biology underlying low RA may be associated with the 256 regulation of sleep (Table 1) . However, on FDR correction this was not statistically significant. There 257 were no significant genetic correlations identified between low RA and ADHD, anxiety, BD, MDD, 258 mood instability, PTSD and schizophrenia. 259
[insert Table 1 here] 260

Association between PRS for low RA and affective disorder phenotypes 261
The findings of analyses assessing the association between low RA PRS and several mood disorder-262 related phenotypes are presented in Table 2 . Positive associations were identified between 263 increased PRS and mood instability at all PRS thresholds, with the exception of genome-wide 264 significance (p<5x10 -8 ). For MDD, small positive associations were found for the low RA PRS at the 265 top three significance thresholds (OR=1·02-1·03), which remained significant after FDR correction 266 (p=0·025-0·05). A positive association with neuroticism was found for the highest threshold (p=0·004, 267 FDR adjusted p=0·021). However, other associations between the remaining PRS thresholds and 268 neuroticism score were not significant. 269 We present the first large-scale genetic study of an objective measure of circadian rest-activity 273 rhythmicity in humans, as well as the first study to examine how common risk SNPs for circadian 274 disruption might be associated with mood disorder phenotypes. The primary GWAS of low RA 275 identified three genome-wide significant SNPs within two independent loci; two of the SNPs 276 highlighted were found to be in relatively high LD (r 2 =0·66-1·00) in many populations 44 
[insert
Genes of interest 282
Of considerable interest is that one of the genes highlighted by GWAS was NFASC, a gene encoding 283 the neurofascin protein. 46 Neurofascin is an L1 family immunoglobulin cell adhesion molecule that 284 interacts with several proteins to anchor voltage-gated Na + channels to the intracellular skeleton in 285 neurons. 46 It is involved in neurite outgrowth and organization of axon initial segments (AIS) during 286 early development. 46 These AIS complexes (comprising neurofascin, ankyrin G (encoded by ANK3), 287 gliomedin and betaIV spectrin) are important for the generation of action potentials and for the 288 maintenance of neuronal integrity. 47 Notably, polymorphisms in ANK3 are robustly associated with 289 BD. 48 The direct binding of neurofascin to ankyrin G at the AIS therefore represents a potentially 290 important biological link between circadian rhythmicity and BD. The NFASC SNPs identified by the 291 GWAS were intronic variants and the NFASC transcript undergoes extensive alternative splicing with 292 not all variants being functionally categorised. 46 The precise influence these variants have on the 293 NFASC gene is currently unclear. 294
One of the genome-wide significant SNPs from the primary GWAS is located within SLC25A17. This 295 gene encodes a peroxisomal solute carrier membrane protein that transports several cofactors from 296 the cytosol to the peroxisomal matrix. 49 Variants of this gene have previously been associated with 297 autism spectrum disorder and schizophrenia. 50 The SLC25A17 gene is also involved in 298 adrenomyeloneuropathy, 51 an inherited condition in which long chain fatty acids accumulate in the 299 central nervous system (CNS) disrupting several brain functions. 52 The SNP identified in the GWAS of 300 low RA (rs9611417) associated with lower expression of RANGAP1, a GTPase activator protein 301 involved in nuclear transport. 53 RANGAP1 is 439kb downstream of rs9611417 and shows relatively 302 high expression in the brain (Supplemental Figure 6) . 303 304 11
The GWAS of RA as a continuous measure highlighted SNPs within the MEIS1 gene. This gene 305 encodes a homeobox transcription factor (TF) protein crucial for the normal development of several 306 tissues, including the CNS. 54, 55 The MEIS1 gene is also associated with myeloid leukaemia 54 and 307 restless leg syndrome 7 (a sleep-wake disorder). 54,55 308 309
Gene-based analyses 310
The gene-based analysis of low RA identified two genes: FOXJ1 on chromosome 17, and ZFYVE21 on 311 chromosome 14. FOXJ1 encodes a forkhead TF protein which has a role in cell differentiation in 312 respiratory, reproductive, immune, and CNS tissues. FOXJ1 is required for the formation of cilia. 56 In 313 mouse models, FOXJ1 was reported to be important for neurogenesis within the forebrain and 314 olfactory bulb. 56 The ZFYVE21 gene encodes the zinc-finger FYVE-type containing 21 protein, 315 involved in cell migration and adhesion. 57 The potential involvement of this gene in the brain and 316 circadian function is currently unclear. 317
For the continuous measure of RA, three genes were identified in the gene-based analysis: CPNE4 318 and C3orf62 (chromosome 3); and RNLS on (chromosome 10). The CPNE4 gene encodes a calcium-319 dependent phospholipid binding protein involved in membrane trafficking and may be involved in 320 intracellular calcium-mediated processes. 58 Deletion of this gene has been associated with earlier 321 age-of-onset of Alzheimer's disease. 59 Currently, the C3orf62 gene is an uncharacterised protein 322 coding gene that has not been functionally annotated. 60 323 RNLS encodes a flavin adenine dinucleotide-dependent amine oxidase, known as Renalase, an 324 enzyme hormone secreted from the kidney into the bloodstream. 61 Renalase is involved in mediating 325 cardiac function and blood pressure by influencing heart rate and has been associated with 326 hypertension, chronic kidney failure and type 1 diabetes prediction. [61] [62] [63] [64] It is worth noting that 327 disrupted circadian rhythmicity has been associated with both diabetes and hypertension in several 328 studies, 4,65,66 and that RNLS has been associated with both treatment outcome and episode 329 recurrence in BD. 67 330 331
Polygenic risk for low RA and psychiatric phenotypes 332
We found little evidence of genetic correlation between low RA and psychiatric phenotypes, even 333 though disruption of circadian rhythmicity is a core feature of mood disorders and polymorphisms in 334 circadian clock genes have been associated with BD within case-control studies. 68,69 Further, as noted 335 above, within the UK Biobank cohort we recently found that lower RA was associated with several 336 adverse mental health outcomes. 24 In the current study, we found some evidence for association 337 12 between greater polygenic risk for low RA and both MDD and neuroticism. Across several PRS 338 thresholds, we identified a more robust association between increasing PRS for low RA and the 339 phenotype of mood instability. Mood instability is a common symptom that cuts across several 340 psychiatric disorders. 70 The possibility of a direct link between genetic loading for circadian 341 disruption and the experience of dysregulated or unstable mood is therefore of considerable 342 interest and merits further investigation. 343
Limitations 344
Several limitations are acknowledged. UK Biobank may not be fully representative of the general UK 345 population, 71 with a possible under-representation of individuals with psychiatric disorders. The 346 scores created using the genome-wide SNPs did not show any associations with lifetime mood 347 disorder diagnoses, mood instability or neuroticism outcomes tested. As only 3 genome-wide 348 significant SNPs were included in these analyses, they may be underpowered. The PRSs (at other 349 thresholds) showed relatively small effects overall on the traits investigated and appeared to explain 350 only a small proportion of the variance within the traits. In terms of phenotyping, the mood 351 instability phenotype was a self-reported subjective measure that may be influenced by response 352 bias. Further, we were unable to identify a direction of causality between RA and the psychiatric 353 phenotypes: approaches to causality such as Mendelian randomisation (MR) were not possible due 354 to the small number of genome-wide significant SNPs identified by both GWAS analyses. 72 355
Conclusions 356
Overall, our findings contribute substantial new knowledge on the genetic architecture of circadian 357 rhythmicity and how this overlaps with mood disorder phenotypes, particularly mood instability. 358
Several of the genetic variants identified are located within or close to genes which may have a role 359 in the pathophysiology of mood disorders. It is hoped that these findings will act as stimulus for 360 future work assessing the complex biological relationships between circadian function and 361 psychiatric disorders. 362 363 13
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